ProQR intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to primarily fund research and development and clinical development to support the ...
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.